The board of directors pharmaceutical company Allergan plc (NYSE:AGN) approved a dividend of USD0.72 per ordinary share for the first quarter of 2018, the company declared on Friday.
This cash dividend is due on 28 March 2018 to shareholders of record at the close of business as of 28 February 2018.
In addition, the company has scheduled its 2018 Annual General Meeting of Shareholders for 2 May 2018 in Dublin, Ireland. The board has set the close of business on 6 March 2018 as the record date for determining shareholders eligible to vote at the meeting.
Headquartered in Dublin, Ireland, Allergan is focused on developing, manufacturing and commercialising branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.
Eli Lilly announces Q1 2026 dividend
Amgen announces Q4 2025 dividend
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government